MNTA Momenta Pharmaceuticals Inc.

12.02
+0.22  (+2%)
Previous Close 11.8
Open 11.89
Price To Book 3.79
Market Cap 1,186,461,770
Shares 98,707,302
Volume 478,072
Short Ratio
Av. Daily Volume 567,814

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial to be completed 2019.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 2020.
M281
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
M281
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data due 2021.
M281
Warm Autoimmune Hemolytic Anemia (wAIHA)

Latest News

  1. Momenta Continues Its Transition
  2. Edited Transcript of MNTA earnings conference call or presentation 2-Aug-19 12:30pm GMT
  3. Momenta Pharmaceuticals Inc (MNTA) Q2 2019 Earnings Call Transcript
  4. Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss
  5. Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates
  6. Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
  7. Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
  8. Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
  9. Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  10. Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
  11. Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
  12. See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.
  13. Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?
  14. Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
  15. Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?
  16. Edited Transcript of MNTA earnings conference call or presentation 2-May-19 12:30pm GMT
  17. Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
  18. Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"